Fresenius Medical Care AG & Co. (Pref) (ETR:FME) received a €95.60 ($113.81) price target from JPMorgan Chase & Co. in a report released on Wednesday. The firm currently has a “buy” rating on the stock. JPMorgan Chase & Co.’s target price indicates a potential upside of 5.99% from the stock’s current price.

FME has been the topic of a number of other research reports. Goldman Sachs Group set a €97.00 ($115.48) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Monday, October 30th. Nord/LB set a €93.00 ($110.71) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Thursday, November 2nd. Berenberg Bank set a €95.60 ($113.81) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Wednesday, December 6th. Morgan Stanley set a €90.00 ($107.14) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Friday, September 15th. Finally, Independent Research set a €88.00 ($104.76) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “neutral” rating in a report on Friday, November 3rd. Ten investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of €90.17 ($107.34).

Shares of Fresenius Medical Care AG & Co. (ETR FME) opened at €90.20 ($107.38) on Wednesday. The firm has a market capitalization of $27,980.00 and a P/E ratio of 22.11. Fresenius Medical Care AG & Co. has a fifty-two week low of €73.87 ($87.94) and a fifty-two week high of €92.08 ($109.62).

WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/12/fresenius-medical-care-ag-95-60-price-target-at-jpmorgan-chase-co.html.

Fresenius Medical Care AG & Co. (Pref) Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.